Table 1 Baseline characteristics of the patients analysed for survival-related end points
Characteristics | All patients, n =1303 |
|---|---|
Sex, male | 880 (68%) |
Age, mean±s.d. | 63±12 |
Albumin, <3.5 g dl−1 | 317 (24%) |
ECOG-PS ⩾2 | 188 (14%) |
Primary tumour site | |
Gastroesophageal junction | 138 (11%) |
Stomach | 1165 (89%) |
Stage at diagnosis, metastatic | 1236 (95%) |
Surgery of primary tumour | 494 (38%) |
Chemotherapy schedules | |
Oxaliplatin-based | 459 (35%) |
Anthracycline-based | 344 (26%) |
Cisplatin-based | 191 (15%) |
Docetaxel-based | 213 (16%) |
Irinotecan-based | 29 (2%) |
Other | 67 (5%) |
Prior perioperative treatment | 155 (12%) |
Lauren classification | |
Intestinal | 482 (37%) |
Diffuse | 652 (50%) |
Indeterminate | 169 (13%) |
Histological grade | |
Grade 1 | 102 (8%) |
Grade 2 | 340 (26%) |
Grade 3 | 580 (44%) |
Not available | 281 (22%) |
Presence of signet ring cells | |
No signet ring cells | 660 (50%) |
Signet ring cells (<50%) | 103 (8%) |
Signet ring cells (⩾50%) | 152 (12%) |
Signet ring cells present with unknown percentage | 202 (16%) |
Not available | 186 (14%) |
Site of metastases | |
Liver | 414 (32%) |
Peritoneum | 641 (49%) |
Bone | 128 (10%) |
Lung | 98 (8%) |
Tumour measurability | |
Only non-measurable disease | 376 (29%) |
Measurable disease | 927 (71%) |
Measurable disease & response assessment available at 3 months | 730 (56%) |
